Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut - 2Opening Potential: Self-awareness and Long lasting Learning
- 3Horses really can smell our fear, new study finds
- 4Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- 5The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- Charity 'feels the pinch' of higher energy prices
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Merz postpones Norway trip for Belgium talks on frozen Russian assets
- Strengthening through Wellness: Individual Preparation Achievement
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- What's your biological age? Experts explain the benefits and risks of at-home tests
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- Easter Island quarry reveals how Polynesians made enigmatic stone statues
- Sahel coups push Africa to top of global democratic declines, report finds
